General Updates

SYNCOM/SE/2026-27 13th August, 2026 Online filing at: www.listing.bseindia.com and https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Tower, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai (M.H.) 400 001 Mumbai- 400051 BSE CODE:524470 NSE SYMBOL: SYNCOMF Sub: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(‘Listing Regulations’): Press Release Dear Madam/ Sir, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III thereto, we hereby submit the Press Release issued by the Company. The Press Release is being submitted for dissemination to the Stock Exchanges and is enclosed herewith for your information and records. Thanking You, Yours Faithfully, For, SYNCOM FORMULATIONS (INDIA) LIMITED CS VAISHALI AGRAWAL COMPANY SECRETARY & COMPLIANCE OFFICE # PRESS RELEASE ## Built on Trust: Syncom Formulations Reports Strong Q1 Growth *Consolidated income and profitability improve significantly over the corresponding quarter, supported by an ethical, prescription-led model* **Mumbai, 11 August 2026** — Syncom Formulations (India) Limited (BSE: 524470 | NSE: SYNCOMF), a WHO-GMP and ISO 9001:2015 certified pharmaceutical company, today reported a strong set of results for the quarter ended 30 June 2026, marked by healthy growth in income and a significant improvement in profitability over the corresponding quarter last year. On a consolidated basis, the Company recorded total income of ₹133.36 crore for Q1 FY 2026-27, against ₹122.94 crore in the corresponding quarter of the previous year — a growth of 8 per cent. Profit before tax rose 59 per cent to ₹32.25 crore from ₹20.29 crore, while profit after tax increased approximately 58 per cent to ₹24.85 crore, compared with ₹15.75 crore a year earlier. Earnings per share improved to ₹0.26 from ₹0.17. Revenue from operations grew to ₹125.53 crore from ₹116.90 crore, an increase of nearly 7 per cent. The Board of Directors has recommended a final dividend of ₹0.10 per equity share of face value ₹1 each for the financial year ended 31 March 2026, subject to the approval of shareholders at the ensuing Annual General Meeting. The performance reflects the steady compounding of a business model the Company has followed for decades — ethical, prescription-led marketing built on long-term relationships with the medical fraternity, supported by consistent quality manufacturing and disciplined cost control. Commenting on the performance, **Mr. Ankit Kedarmal Bankda, Chairman & Whole-time Director**, said: "This quarter reflects the strength of the foundation we have built — quality manufacturing, an ethical prescription-led model, and the trust of the medical community we have served for decades. Our focus remains on responsible, sustainable growth and on making quality medicines accessible to every patient we can reach." **A Deep Domestic Footprint** Syncom's domestic business operates through six specialised divisions, supported by a dedicated field force of over 1,000 medical representatives with a genuine pan-India presence, engaging closely with the medical fraternity across gynaecology, fertility, gastroenterology, critical care and veterinary medicine. Within women's healthcare, the Company's Ovafresh and Ovafresh-M brands, marketed under the Cratus Evolve portfolio, rank among the leading brands in the IVF and gynaecology segment nationally. Through its generics and OTC arm, Syncom markets consumer brands including Megajoy, Asardar and Kabz All Fine, which enjoy wide pharmacy availability across the country. A dedicated cold chain network ensures temperature-sensitive formulations reach patients with their quality fully preserved. **A Growing International Presence** Present in international markets since 2001, Syncom today exports to over 15 countries and holds product registrations and approvals from more than 10 international regulatory authorities. **Manufacturing Backbone** All products are manufactured at the Company's WHO-GMP approved facility at Pithampur, Madhya Pradesh — a modern plant of approximately 2,50,000 sq. ft. producing tablets, capsules, liquid orals, injectables, ophthalmics and topical preparations. Syncom Formulations (India) Limited is listed on the BSE and the National Stock Exchange of India, with its registered office in Mumbai.